The effect of tocilizumab on clinical signs and laboratory findings in rheumatoid arthritis patients resistant to methotrexate

The effect of tocilizumab on clinical signs and laboratory findings in rheumatoid arthritis... Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that mainly affects joint damage followed by increased morbidity and mortality rates. The progressive increase of inflammation factors, especially IL-6, is seen during the course of this condition. The aim of this study was to evaluate the effect of tocilizumab (TCZ) in patients with severe to moderate resistant RA with an inadequate response to treatment with disease-modifying antirheumatic drugs (DMARDs). We also reviewed the safety of the drug and related complications. Twelve selected RA patients received 8 mg/kg of TCZ every 4 weeks for over 24 weeks; we evaluated inflammatory factor like ESR, lipid profile, comprehensive physical exam, and RA activity like Disease Activity Score (DAS) 28, Short Form (36) Health Survey (SF-36), and ACR50 to calculate the swollen and tender joint counts. DMARDs were simultaneously administered. First-level response and secondary response were defined as reaching the American College of Rheumatology 20% response criteria (ACR20) within 24 weeks of treatment and Disease Activity Score (DAS) 28, Short Form (36) Health Survey (SF-36), and ACR50, respectively. All patients achieved ACR20 after 24 weeks and 83% reached ACR50 (p < 0.001). DAS28 decreased from 6.93 ± 2.11 at baseline to 1.29 ± 0.95 at the end of 28 weeks (p < 0.001). SF-36 increased from 28 ± 1.43 to 61.42 ± 15.66 at the end of the study (p < 0.001). SF-36 physical component summary scores also increased from 42 ± 4.98 at baseline to 88.17 ± 2.96 at the end of the study (p < 0.001). We observed that TCZ caused a rapid and sustained improvement in all disease activity indicators such as CRP, ESR, swelling and tender joint count, and morning stiffness duration in RA patients’ refractory to methotrexate. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Comparative Clinical Pathology Springer Journals

The effect of tocilizumab on clinical signs and laboratory findings in rheumatoid arthritis patients resistant to methotrexate

Loading next page...
 
/lp/springer_journal/the-effect-of-tocilizumab-on-clinical-signs-and-laboratory-findings-in-1oDIN8jKrf
Publisher
Springer London
Copyright
Copyright © 2017 by Springer-Verlag London Ltd.
Subject
Medicine & Public Health; Pathology; Hematology; Oncology
eISSN
1618-565X
D.O.I.
10.1007/s00580-017-2513-4
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial